Biotech giant Amgen announced Jan. 17 that the U.S. Food and Drug Administration approved changes to the label of its multiple myeloma drug Kyprolis. Data from a Phase 3 study showed that overall survival increased by 7.6 months in patients using Kyprolis alongside dexamethasone, and that the risk of death decreased 21 percent. "Overall survival…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
